Immunovia (BATS-CHIXE:IMMNOS) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

IMMNOS Panoramica delle azioni

A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.

IMMNOS analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 94.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 76.7% all'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( SEK949K )

Le azioni sono altamente illiquide

Ha meno di 1 anno di pista di cassa

Non ha una capitalizzazione di mercato significativa ( SEK552M )

Immunovia AB (publ) Concorrenti

Belluscura

AIM:BELL

UK£21.1m

ANGLE

AIM:AGL

UK£26.6m

EMV Capital

AIM:EMVC

UK£12.8m

Creo Medical Group

AIM:CREO

UK£94.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Immunovia
Prezzi storici delle azioni
Prezzo attuale dell'azione	SEK 34.30
Massimo di 52 settimane	SEK 63.05
Minimo di 52 settimane	SEK 30.28
Beta	1.41
1Variazione di 1 mese	0%
Variazione a 3 mesi	-4.08%
Variazione di 1 anno	-44.68%
3Variazione a 3 anni	-79.87%
Variazione a 5 anni	n/a
Variazione dall'IPO	-77.15%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	IMMNOS	GB Medical Equipment	GB Mercato
7D	0%	-2.2%	-0.5%
1Y	-44.7%	6.5%	7.9%

Ritorno vs Industria: IMMNOS ha avuto una performance inferiore rispetto al UK Medical Equipment che ha registrato un rendimento 6.7 % nell'ultimo anno.

Rendimento vs Mercato: IMMNOS ha avuto una performance inferiore al mercato UK che ha registrato un rendimento 13.1 % nell'ultimo anno.

Volatilità dei prezzi

Is IMMNOS's price volatile compared to industry and market?
IMMNOS volatility
IMMNOS Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.9%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.5%

Prezzo delle azioni stabile: IMMNOS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di IMMNOS nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	64	Philipp Mathieu	www.immunovia.com

Immunovia AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Immunovia con la sua capitalizzazione di mercato?
IMMNOS statistiche fondamentali
Capitalizzazione di mercato	SEK 551.76m
Guadagni(TTM)	-SEK 147.90m
Ricavi(TTM)	SEK 949.00k

581.4x

Rapporto P/S

-3.7x

Rapporto P/E

IMMNOS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IMMNOS Conto economico (TTM)
Ricavi	SEK 949.00k
Costo del fatturato	SEK 4.15m
Profitto lordo	-SEK 3.20m
Altre spese	SEK 144.70m
Guadagni	-SEK 147.90m

Ultimi guadagni dichiarati

Sep 30, 2022

Prossima data di guadagno

Feb 09, 2023

Utile per azione (EPS)	-6.54
Margine lordo	-336.78%
Margine di profitto netto	-15,584.62%
Rapporto debito/patrimonio netto	0%

Come si è comportato IMMNOS nel lungo periodo?

Vedi performance storica e confronto

IMMNOS Panoramica delle azioni

Premi

Analisi del rischio

Immunovia AB (publ) Concorrenti

AIM:BELL

UK£21.1m

AIM:AGL

UK£26.6m

AIM:EMVC

UK£12.8m

AIM:CREO

UK£94.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Recent updates

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently bought kr186k worth of stock

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Revenue in line with expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Immunovia AB Announces Results from Study in Their Development Pipeline

New 90-day low: kr111

Director recently bought kr144k worth of stock

New 90-day low: kr122

Immunovia AB (Publ) Announces Appointment of Members of Nomination Committee

Immunovia AB (publ) Announces Management Changes

Immunovia AB (Publ) Announces Completion of Analysis from the Immray Pancan-D Verification Study

Immunovia Announces Positive Results from the Immray Pancan-D Verification Study

Immunovia AB (Publ) Appoints Mats Grahn as New Member of the Board of Directors

Immunovia Announces CEO Transition, Effective November 1, 2020